- Home
- VSTM vs TLSA Comparison
VSTM vs TLSA Comparison
Compare VSTM & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | TLSA |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.8M | 145.1M |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VSTM | TLSA |
|---|---|---|
| Price | $7.58 | $0.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 611.7K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,914,000.00 | N/A |
| Revenue This Year | $282.64 | N/A |
| Revenue Next Year | $72.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 209.14 | N/A |
| 52 Week Low | $3.43 | $0.87 |
| 52 Week High | $10.82 | $2.35 |
Technical Indicators
Market Signals| Indicator | VSTM | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 30.83 |
| Support Level | $6.68 | N/A |
| Resistance Level | $7.86 | $1.20 |
| Average True Range (ATR) | 0.39 | 0.08 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 19.48 | 3.61 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.